Pharvaris NV said its CHAPTER-3 pivotal Phase 3 trial of once-daily oral deucrictibant extended-release tablets met all primary and secondary efficacy endpoints for preventing hereditary angioedema (HAE) attacks. Across patients with HAE Type 1, Type 2 and HAE with normal C1 inhibitor, the 40-milligram treatment reduced the mean monthly attack rate by 83% versus placebo over 24 weeks. Among 80 patients with HAE Type 1 or Type 2, the reduction was 87%. Protection began within the first week and continued through the study, while most adverse events were mild or moderate. No treatment-related serious adverse events were reported, and one patient in each group discontinued because of an adverse event. Pharvaris plans to submit a New Drug Application to the U.S. Food and Drug Administration in early 2027. The CHAPTER-4 open-label extension remains ongoing, and topline data from the separate Phase 3 CREAATE study in acquired angioedema are expected in the first quarter of 2027. Following the results, Oppenheimer raised its price target for Pharvaris from $50 to $75 and maintained an Outperform rating. Pharvaris shares were reported up 17.02% at $41.25 on Tuesday, after previously rising more than 25% in premarket trading.